Dong-A Esteee partner of the new Robo, Phase III clinical trials on new drugs – Diodeo

The DA-9801 (NB-01), a natural substance of diabetic neuropathy, has been approved for clinical use by the end of this year. Three phase

Importation of Neurobore technology (license withdrawal) from & # 39; DA-9801 & # 39; who completed clinical phase 2 of the US operation in Dong Aeste in January. Dong Aeste must receive up to $ 180 million (about 190 billion won) in commissions (milestones) for each stage of the clinic and marketing, including contracts worth $ 2 million. dollars. In addition, Dong-A has received a 5% interest in New Robo and will receive royalties upon commercialization.

The "DA-9801" developed by DongAesty has a mechanism of pain relief, caused mainly by diabetic patients, incorporating natural ingredients with badgesic effect and nerve regeneration effect.

That same month, Neurobore is preparing to apply for a Phase 1 clinical trial in the United States based on the preclinical (animal experiments) results from Dong-A Industrial Co., Ltd. conducted in Korea for DA-9803, a naturally occurring substance. C & # 39; is.

At that time, the company decided to receive $ 5 million (about 5.3 billion won) from Newrobo and 24% from Newrobo as a prerequisite for the transfer of "DA-9803". & # 39; DA-9803 & # 39; has been developed for the treatment of Alzheimer's dementia.

Neurobe has partnered with a team of highly experienced and experienced leaders to increase the success rate of clinical trials. In addition, the company has recruited staff to develop its sales activities.

The management team is made up of John Brooks New Robo and Chair of the Technical Advisory Committee, Dr Roy Freman, Mark Vasabel, Chief Medical Officer, and Nadan Padukone, Deputy Director of Business Development.

John Brooks is the founder of seven companies in the life sciences sector and a representative of the American center Jocelyn Diabetes. Dr. Roy Freeman is the co-founder of New Robo and a neuro-diabetes expert at Harvard Medical School. Dr. Mark Versabel, who has 25 years of clinical experience in the fields of neuropathic pain, neurology and mental illness, is an expert in early development and business management of diabetes.

"We will be able to provide clinicians with new treatment options for patients with diabetic neuropathy and Alzheimer's with many medical needs," said Newrobo officials.

[email protected]